Top Markets
#1 Status Status +21.05%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.55%
#3 Fake World Assets Fake World Assets +14.92%
#4 Ontology Gas Ontology Gas +12.78%
#5 GoPlus Security GoPlus Security +12.22%
#6 DMT-NAT DMT-NAT +8.79%
#7 Nillion Nillion +6.92%
#8 Provenance Blockchain Provenance Blockchain +6.68%
#9 Janction Janction +6.46%
#10 Bedrock Bedrock +5.82%
Coin of the day
Status Status
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Rang în acțiuni #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Preț acțiune
$0.6379482
Ultima sincronizare: 2023-05-22
Capitalizare de piață
$5.98M
Schimbare (1 zi)
-0.44%
Schimbare (1 an)
0.00%
Țară
FR
Tranzacționează Nicox S.A. (COX)

Categorie

Healthcare
Venituri pentru Nicox S.A. (COX)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Nicox S.A., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Nicox S.A. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE